YTYasemin Bakkal Temi

Yasemin Bakkal Temi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yasemin Bakkal Temi has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma

    by İlkay Çıtakkul, Hayati Arvas, Mert Karaoğlan, Bahadır Köylü, Nazan Demir, Gözde Balkaya Aykut, Elif Şahin, Mesut Yılmaz, Zuhat Urakçı, Duygu Bayır Garbioğlu, et al.

    Second-line chemotherapy is widely used in metastatic urothelial carcinoma after progression on first-line platinum-based therapy, but its independent contribution to survival, as opposed to selection of healthier patients, remains unclear. In this multicenter retrospective cohort of 142 patients treated with first-line platinum-based chemotherapy across seven Turkish centers, overall survival (OS) from first-line progression was compared between patients who received second-line chemotherapy (n = 80) and those who did not (n = 62), using multivariable Cox regression, inverse probability of treatment weighting (IPTW), propensity-score matching, landmark analysis, and a time-dependent Cox model. Median OS was 7.4 versus 4.7 months (log-rank p = 0.064). Second-line chemotherapy was independently associated with improved OS on multivariable analysis (adjusted hazard ratio [aHR] 0.620; 95% confidence interval [CI] 0.423–0.907; p = 0.014); Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 (aHR 3.881; p = 0.001) and lower albumin (aHR 0.671; p = 0.018) were also independent predictors. The association remained significant after IPTW (HR 0.648; p = 0.025) and after a time-dependent Cox model (HR 0.632; p = 0.019), and was unchanged in ECOG-restricted and Bellmunt-adjusted analyses (p = 0.008, p = 0.029); it narrowly missed significance after propensity-score matching (HR 0.645; p = 0.051) and did not reach significance in the 3-month landmark analysis (HR 0.743; p = 0.180). Power was limited (~49%). In a time-dependent Cox model—the analysis least susceptible to immortal-time bias, as it retains the full cohort and classifies pre-treatment person-time as unexposed—second-line chemotherapy remained independently associated with improved OS (HR 0.632; p = 0.019), closely consistent with the primary multivariable estimate. The conventional Cox, IPTW, and propensity-score-matched analyses, which treat second-line receipt as a baseline exposure, were directionally concordant but share a common time-related bias and are therefore not independent confirmations. ECOG performance status was a consistent predictor throughout.

  • Open Access

    Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study

    by Pervin Can Şancı, Mustafa Seyyar, Anil Karakayali, Murat Akyol, Yasemin Bakkal Temi, Devrim Çabuk, Kazım Uygun, Umut Kefeli

    Background/Objectives: Gastric cancer remains a leading cause of cancer-related mortality worldwide, with a significant number of patients diagnosed at locally advanced stages. While perioperative chemotherapy and surgical resection are the standard treatments, patient outcomes remain heterogeneous. This study aimed to investigate the prognostic and predictive effects of Body Mass Index (BMI) on pathological response, progression-free survival (PFS), and overall survival (OS) in patients receiving neoadjuvant chemotherapy. Methods: This retrospective, observational cohort study included 192 patients with locally advanced gastric cancer who underwent curative gastrectomy and neoadjuvant chemotherapy between 2018 and 2023. Patients were categorized based on an optimal BMI cutoff value of 24.9 kg/m2. Results: Patients with a BMI ≥ 24.9 kg/m2 demonstrated a 41% lower 5-year mortality risk compared to those with a lower BMI (HR = 0.59; 95% CI: 0.35–0.99; p = 0.044). The high BMI group had a significantly longer average PFS (54.1 months) compared to the low BMI group (41.4 months). High BMI was associated with a significantly reduced risk of progression (HR: 0.61; 95%CI: 0.38–0.97; p = 0.038. Log-linear regression confirmed that the complete response rate was 73.7% lower in patients with low BMI. Conclusions: BMI threshold of ≥24.9 kg/m2 is associated with improved pathological response and long-term survival in patients with locally advanced gastric cancer receiving neoadjuvant chemotherapy. These findings suggest that BMI potentially reflects the impact of nutritional status on treatment tolerability and oncological outcomes.

  • Prognostic value of the PLACE score in a Turkish cohort of metastatic pleural mesothelioma

    by İlKay Çıtakkul, Yasemin Bakkal Temi, Hilmi Zengin, Mertcan Önen, Ece Baydar, Umut Kefeli, Devrim Çabuk, Kazım Uygun

    Aims: Pleural mesothelioma is an aggressive malignancy with poor prognosis and limited therapeutic options. Reliable prognostic models are essential for risk stratification and clinical decision-making. The recently developed PLACE score has shown promising results in Chinese populations; however, its generalizability remains uncertain. This study aimed to externally validate the PLACE prognostic score in a Turkish cohort of patients with metastatic epithelioid pleural mesothelioma. Methods: This retrospective cohort study included patients diagnosed with metastatic epithelioid pleural mesothelioma at a single tertiary center between January 2016 and September 2025. Clinical and laboratory data at diagnosis were collected, and the PLACE score was calculated for each patient. Overall survival (OS) was analyzed using the Kaplan–Meier method, and differences between risk groups were compared using the log-rank test. Cox proportional hazards regression analysis was performed to evaluate the association between prognostic variables and survival. The discriminative ability of the PLACE score was assessed using receiver operating characteristic (ROC) curve analysis. Results: A total of 48 patients were included, with a median age of 66 years. According to the PLACE score, 33.3% of patients were classified as low-risk and 66.7% as high-risk. The median overall survival was 21.06 months. Patients in the low-risk group had significantly longer survival compared to the high-risk group (37.98 vs. 15.6 months, p=0.033). The PLACE score demonstrated limited discriminative ability, with an area under the curve (AUC) of 0.617 (95% CI: 0.413–0.821). In Cox regression analysis, high-risk patients had a significantly increased risk of mortality (HR: 2.28, 95% CI: 1.04–4.95, p=0.037). In multivariable analysis, the PLACE risk group remained an independent predictor of overall survival. Conclusion: The PLACE score retains prognostic significance in Turkish patients with metastatic pleural mesothelioma but demonstrates reduced discriminative performance compared to the original study. These findings emphasize the need for external validation and potential population-specific recalibration of prognostic models.

  • Open Access

    EASIX Score as an Independent Prognostic Marker in De Novo Metastatic Pancreatic Cancer

    by İlkay Çıtakkul, Yasemin Bakkal Temi, Zehra Aytin, Ece Baydar, Umut Kefeli, Devrim Çabuk, Kazım Uygun

    Background and Objectives: Metastatic pancreatic ductal adenocarcinoma carries a dismal prognosis and there is an unmet need for simple, widely available prognostic biomarkers to guide risk stratification and treatment planning. This study aimed to evaluate whether baseline EASIX score, calculated from routine laboratory parameters (LDH, creatinine, platelet count), predicts overall survival (OS) in patients with de novo metastatic pancreatic cancer. Materials and Methods: We performed a retrospective cohort study at a single tertiary center (Medical Oncology Department, Kocaeli University Faculty of Medicine) including 332 patients diagnosed with de novo metastatic pancreatic ductal adenocarcinoma between January 2019 and October 2025. Baseline EASIX was calculated using LDH, creatinine, and platelet count. Statistical analyses included ROC analysis with Youden index to determine exploratory cut-off, Kaplan–Meier survival estimation with log-rank test, and univariate and multivariate Cox proportional hazards regression to identify independent prognostic factors. The primary endpoint was OS, defined as time from initiation of first-line therapy to death from any cause. Results: A total of 332 patients were included. Median OS was 8.0 months overall. Patients with high EASIX (>2.505) had significantly shorter median OS compared with low EASIX patients (8.4 vs. 27.6 months, p < 0.001). ROC analysis was considered exploratory for overall survival; therefore, an additional fixed-time (12-month mortality) ROC analysis was performed to provide a discrimination estimate accounting for censoring. The AUC for EASIX was 0.887 (95% CI: 0.816–0.958), and the exploratory cut-off determined was 2.505 (sensitivity 96.95%, specificity 72.97%). In multivariate Cox regression, high EASIX remained an independent predictor of worse OS (HR 4.124; 95% CI: 2.011–8.457; p < 0.001) after adjustment for relevant covariates. Conclusions: Baseline EASIX score is an independent prognostic marker for overall survival in de novo metastatic pancreatic cancer, based on routine laboratory tests, and may facilitate exploratory risk stratification. Prospective validation in independent cohorts is warranted before clinical implementation.


  • Real-World Outcomes of Irinotecan–Bevacizumab Therapy in Recurrent Brain Tumors: A Retrospective Cohort Study

    by Mustafa Seyyar, Pervin Can Şancı, Ali Kalem, Burak Mete, Tolga Köşeci, Anıl Karakayalı, Mehmet Uzun, Teoman Sakalar, Yasemin Bakkal Temi, Melike Yazıcı, et al.

    Aim: Although the irinotecan–bevacizumab (IB) combination is a frequently used treatment option in recurrent brain tumors, clinical benefit shows heterogeneity among patient subgroups. This study aimed to evaluate clinical and prognostic factors associated with early-stage mortality and overall survival (OS) in patients receiving IB treatment. Material and Methods: Seventy-eight brain tumor patients who received IB treatment between 2015 and 2023 were retrospectively evaluated. Patients with complete clinical and radiological data were included in the study. The demographic, clinical, and pathological characteristics of the patients were recorded. The timing of the initiation of IB therapy was categorized according to whether it was started at the first recurrence or at the second and subsequent recurrences. Factors associated with early-stage mortality (≤6 months) were determined using log-linear regression analysis, while independent prognostic factors affecting GSK were determined using the Cox proportional hazards regression model. Results: The mean age of patients was 53.01±12.78 years, and the mean follow-up period was 9.47 months. The mortality rate within the first 6 months was determined to be 44.9%. Early-stage mortality was found to be significantly associated with multilobular tumor localization (p=0.037) and initiation of IB therapy at ≥2nd stage (p=0.036). In the log-linear regression analysis, the probability of survival beyond 6 months was 5.05 times lower (RR=0.198, 95% CI: 0.054-0.735) in multilobular localization, while in those who started IB at ≥2nd node, it was 4.40 times lower (RR=0.227, 95% CI: 0.069-0.748). In the multivariate Cox regression analysis, starting IB at ≥2nd line (HR: 2.35, 95% CI: 1.09-5.07, p=0.029), the presence of IDH mutation (HR: 1.98, 95% CI: 1.09-3.58, p=0.025), and age (HR: 1.03, 95% CI: 1.01-1.05, p=0.015) were identified as independent prognostic factors for GSK. Conclusion: This retrospective cohort study based on real-world data demonstrates that the clinical benefit of the IB combination shows significant heterogeneity across patient subgroups. Multilobar tumor location and initiation of IB therapy in the late stages of recurrence are associated with early mortality and poorer survival. Our findings emphasize that IB therapy in recurrent brain tumors should be administered in a personalized manner, considering patient selection and treatment sequence, rather than as a routine approach.

  • Open Access

    The Pretreatment Glucose-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Ovarian Cancer

    by Ece Baydar, Yasemin Bakkal Temi, İlkay Çıtakkul, Devrim Çabuk, Umut Kefeli, Kazım Uygun

    Background/Objectives: This study aimed to assess the prognostic significance of the glucose-lymphocyte ratio (GLR) prior to therapy in individuals with epithelial ovarian cancer. Methods: This retrospective cohort study included 326 patients with epithelial ovarian cancer who were treated from 2011 to 2025. The GLR was computed utilizing pre-treatment fasting blood glucose levels and absolute lymphocyte numbers. The optimal GLR cutoff value was established by receiver operating characteristic (ROC) analysis. Overall survival (OS) and disease-free survival (DFS) were assessed utilizing Kaplan–Meier analysis and Cox regression models. Additional sensitivity analyses were performed excluding patients with diabetes mellitus and by testing the interaction between GLR and neoadjuvant chemotherapy. Results: The optimal GLR cutoff value was 3.42. Patients were classified into low-GLR (≤3.42; n = 190) and high-GLR (>3.42; n = 136) groups. Patients with high GLR levels (>3.42) had a median OS of 58 months, which was significantly shorter than the 151 months for patients with low GLR levels (≤3.42) (p < 0.001). They also had a median DFS of 17 months, which was significantly shorter than the 49 months for patients with low GLR levels (p < 0.001). Multivariable Cox regression analysis showed that a higher GLR is an independent prognostic factor related to shorter overall survival (HR: 1.561; 95% CI: 1.078–2.261; p = 0.018). Findings remained consistent after excluding patients with diabetes mellitus. The group with a high GLR had a greater rate of disease progression (55.1% vs. 29.5%, p < 0.001). Conclusions: The pre-treatment GLR may serve as a simple and readily available prognostic biomarker in epithelial ovarian cancer, potentially supporting basic risk stratification; however, external validation is required.

  • Open Access

    Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    by Baris Koksal, Hasan Cagri Yildirim, Deniz Can Guven, Fatih Kose, Gorkem Koymen, Ozlem Ozdemir, Ugur Ozberk, Efnan Algin, Murad Guliyev, Nebi Serkan Demirci, et al.

    Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in Türkiye between January 2014 and March 2025. Clinical, pathological, and molecular data—including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification—was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan–Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3–4 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.


  • Real-World Validation of the KELIM Score for Predicting Chemosensitivity and Survival in Advanced Ovarian Cancer

    by Yasemin Bakkal Temi, İlKay Çitakkul, Ece Baydar, Sibel Balcı, Devrim Çabuk, Umut Kefeli, Kazım Uygun

    Aim: We evaluated the prognostic significance of the KELIM score, which is derived from CA-125 kinetics, in predicting survival outcomes among patients with advanced epithelial ovarian cancer in a real-world clinical context. Material and Methods: This retrospective study analyzed 238 patients with stage III-IV ovarian cancer treated between 2017-2024. KELIM scores, calculated from CA-125 kinetics during the first 100 treatment days, were categorized as high (favorable, >0.9) or low (unfavorable, ≤0.9) based on the ROC analysis. Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses. Results: Patients with low KELIM scores had significantly shorter median overall survival (33 vs. 68 months, p < 0.001) and progression-free survival (11 vs. 18 months, p < 0.001) than those with high scores. Multivariate Cox regression analysis identified a low KELIM score as a significant predictor of poor overall survival (HR, 4.062; 95% CI, 2.711–6.087; p < 0.001). Additionally, disease progression was more frequent in patients with a low KELIM score (89.4%) than in those with a high KELIM score (69.9%, p = 0.001). Conclusion: The KELIM score serves as a practical and accessible prognostic biomarker for advanced ovarian cancer with the potential to inform early treatment decisions for patients who are unlikely to benefit from standard chemotherapy. Further prospective studies are warranted to validate their roles in personalized therapeutic strategies.


  • Open Access

    Real-World Evaluation of the HELPP Score and CALLY Index for Preoperative Prognostic Stratification in Resectable Pancreatic Ductal Adenocarcinoma

    by İlkay Çıtakkul, Umut Kefeli, Khatira Shukurova, Zehra Aytin, Yasemin Bakkal Temi, Ece Baydar, Kazım Uygun, Devrim Çabuk

    Background/Objectives: Preoperative prognostic assessment is essential for optimizing treatment strategies in pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate and compare the prognostic value of the Heidelberg Pancreatic Prognostic (HELPP) score and the C-reactive protein–albumin–lymphocyte (CALLY) index in patients with resectable PDAC. Methods: We retrospectively analyzed clinical and laboratory data of 109 patients with resectable PDAC who underwent curative-intent surgery and adjuvant therapy. Patients were stratified based on preoperative HELPP and CALLY scores. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis, while independent prognostic factors were determined through multivariate Cox regression. Results: Kaplan–Meier survival analyses demonstrated that a HELPP score > 3 and a low CALLY index (≤1.029) were significantly associated with worse OS and DFS (log-rank p < 0.05). In multivariate analysis, the HELPP score was identified as an independent predictor of survival, whereas the CALLY index, although associated with survival in univariate analysis, did not reach statistical significance. In ROC analysis, both models exhibited acceptable discrimination, with the HELPP score achieving superior AUC values in predicting 1-year OS compared to the CALLY index. Conclusions: The HELPP score demonstrated independent prognostic value in multivariate analysis and may serve as a robust preoperative tool in resectable PDAC. The CALLY index, although not independently significant in multivariate analysis, showed strong prognostic separation in Kaplan–Meier survival analyses and may still aid in preoperative risk stratification, particularly where access to comprehensive scoring systems is limited.